Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.

导出原文传递

翻译打印收藏纠错

作者： Shayan,Dioun ^[1] ; Ling,Chen ^[2] ; Alexander,Melamed ^[1] ; Allison,Gockley ^[1] ; Caryn M,St Clair ^[3] ; June Y,Hou ^[1] ; Fady,Khoury-Collado ^[3] ; Chin,Hur ^[1] ; Elena,Elkin ^[3] ; Melissa,Accordino ^[1] ; Dawn L,Hershman ^[3] ; Jason D,Wright ^[1]

作者单位： Columbia University College of Physicians and Surgeons, New York, New York, USA. ^[1] New York Presbyterian Hospital, New York, New York, USA. ^[2] Herbert Irving Comprehensive Cancer Center, New York, New York, USA. ^[3] Joseph L. Mailman School of Public Health, Columbia University, New York, New York, USA. ^[4]

关键词 cost-effectiveness dostarlimab pembrolizumab recurrent endometrial cancer recurrent uterine cancer

主题词人类(Humans);女(雌)性(Female);费用效益分析(Cost-Benefit Analysis);DNA错配修复(DNA Mismatch Repair);肿瘤复发, 局部(Neoplasm Recurrence, Local);质量校正寿命(Quality-Adjusted Life Years);子宫内膜肿瘤(Endometrial Neoplasms)

DOI 10.1111/1471-0528.17338

PMID 36330672

发布时间 2022-12-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交